IP Library Granted Patent US 11,786,607
Granted Patent B2
US 11,786,607 · App. 16/623,069 · Granted Oct 17, 2023

RNA formulations

Inventors: Stephen Hoge (Brookline, MA); Joseph Schariter (Waltham, MA); Charles Bowerman (Waltham, MA); Michael H. Smith (Needham, MA); Yan Xia (Natick, MA)
Assignee: ModernaTX, Inc.
A61K47/6931A61K31/7105A61K47/543
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,786,607
App. No.
16/623,069
Granted
Oct 17, 2023
Kind
B2
Abstract

This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins.

Claims (35)

1. A composition comprising an enriched population of lipid nanoparticles (LNPs), wherein the LNPs have an outer shell and an inner core and comprise an ionizable lipid, a phospholipid, a poly(ethylene glycol) (PEG) lipid, wherein at least 50% of the LNPs comprise mRNA encapsulated within the inner core and wherein the outer shell comprises at least 95% of the total PEG lipid in the LNP, and wherein the LNP's are formed by a nanoprecipitation process including a step in which additional PEG lipid was added to the LNP's after an initial nanoprecipitation reaction.

2. The composition of claim 1 , further comprising a structural lipid.

3. The composition of claim 2 , wherein at least 50% of the LNPs have a ratio of ionizable lipid:phospholipid:structural lipid of 35-50:30-40: 20-30.

4. The composition of claim 2 , wherein:

(a) the LNP is insensitive to accelerated blood clearance upon repeated administration in vivo within 10 days;

(b) at least 50% of the LNPs have 1-5 inner shells;

(c) the structural lipid is cholesterol;

(d) 10-30% of the LNP, exclusive of mRNA, is the structural lipid; and/or

(e) the outer shell is comprised of 10-30% of the structural lipid.

5. The composition of claim 1 , wherein at least 50% of the LNPs have an outer shell fluidity value of greater than a threshold polarization level.

6. The composition of claim 1 , wherein a quantitative value of the amount of mRNA encapsulated in the LNP is generated using an ion-exchange (IEX) chromatography assay.

7. The composition of claim 1 , wherein:

(a) at least about 50% of the LNPs in the population have mRNA encapsulated therein, as determined by ion-exchange chromatography (IEX); and/or

(b) the LNPs have an encapsulation efficiency of at least about 50% as determined by ion-exchange chromatography (IEX).

8. The composition of claim 1 , wherein the phospholipid is DSPC.

9. A composition comprising a population of lipid nanoparticles (LNPs), the LNPs comprise an ionizable amino lipid, a poly(ethylene glycol) (PEG) lipid, a phospholipid, wherein:

(a) at least about 50% of the LNPs in the population have mRNA encapsulated therein, as determined by ion-exchange chromatography (IEX), and wherein the LNP's are formed by a nanoprecipitation process including a step in which additional PEG lipid was added to the LNP's after an initial nanoprecipitation reaction; and/or

(b) the LNPs have an encapsulation efficiency of at least about 50% as determined by ion-exchange chromatography (IEX).

10. The composition of claim 9 , further comprising a structural lipid.

11. The composition of claim 10 , wherein the structural lipid is cholesterol or a cholesterol derivative.

12. The composition of claim 9 , wherein the composition is enriched for LNPs:

(a) lacking B1a cell-stimulating phospholipid epitopes, and/or

(b) lacking scavenger receptor ligands.

13. The composition of claim 12 , wherein at least about 50% of the LNPs:

(a) lack B1a cell-stimulating phospholipid epitopes, and/or

(b) lack scavenger receptor ligands.

14. The composition of claim 9 , wherein the composition is enriched for LNPs having a majority of the total phospholipid present in the outer LNP shell.

15. The composition of claim 14 , wherein at least about 50% of the LNPs have the majority of the total phospholipid present in the outer LNP shell.

16. The composition of claim 9 , wherein the composition is enriched for LNPs having more than 50% of the total phospholipid present on the surface.

17. The composition of claim 16 , wherein at least about 50% of the LNPs have more than 50% of the total phospholipid present on the surface.

18. The composition of claim 9 , wherein the composition is enriched for LNPs having a majority of the total PEG lipid present in the outer LNP shell.

19. The composition of claim 18 , wherein at least about 50% of the LNPs have the majority of the total PEG lipid present in the outer LNP shell.

20. The composition of claim 9 , wherein the composition is enriched for LNPs having more than 50% of the total PEG lipid present on the surface.

21. The composition of claim 20 , wherein at least about 50% of the LNPs have more than 50% of the total PEG lipid present on the surface.

22. The composition of claim 13 , wherein the phospholipid is DSPC.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2020
From: HOGE, STEPHEN; SCHARITER, JOSEPH; BOWERMAN, CHARLES; SMITH, MICHAEL H.; XIA, YAN
To: MODERNATX, INC.
Reel/Frame 051791/0442 →
Cited By (7)
US 12,521,577 US 12,551,734 US 12,582,609 US 12,622,960 US 12,629,412 US 12,667,543 US 12,685,787